Aarkstore - Resistant Pseudomonas Aeruginosa Infections

1. Healthcare Market Research Reports Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014 For More Information Visit : www.aarkstore.com

2. Summary ‘Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2014’, provides an overview of the Resistant Pseudomonas AeruginosaInfections’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Resistant Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.  For More Information Visit : www.aarkstore.com

3. Scope - The report provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas Aeruginosa Infections- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Resistant Pseudomonas Aeruginosa Infections and enlists all their major and minor projects- The report summarizes all the dormant and discontinued pipeline projects - A review of the Resistant Pseudomonas Aeruginosa Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages- A detailed assessment of monotherapy and combination therapy pipeline projects- Coverage of the Resistant Pseudomonas Aeruginosa Infections pipeline on the basis of target, MoA, route of administration and molecule type- Latest news and deals relating related to pipeline products For More Information Visit : www.aarkstore.com

4. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Develop strategic initiatives by understanding the focus areas of leading companies- Identify and understand important and diverse types of therapeutics under development for Resistant Pseudomonas Aeruginosa Infections- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline- Devise corrective measures for pipeline projects by understanding Resistant Pseudomonas Aeruginosa Infections pipeline depth and focus of Indication therapeutics- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline For More Information Visit : www.aarkstore.com

5. Table of Content List of Tables 5List of Figures 5Introduction 6Global Markets Direct Report Coverage 6Resistant Pseudomonas Aeruginosa Infections Overview 7Therapeutics Development 8Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Overview 8Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis 9Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies 10Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 11Resistant Pseudomonas Aeruginosa Infections - Pipeline Products Glance 12Clinical Stage Products 12Early Stage Products 13Resistant Pseudomonas Aeruginosa Infections - Products under Development by Companies 14 For More Information Visit : www.aarkstore.com

6. List of Tables Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections, H2 2014 8Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis, H2 2014 9Number of Products under Development by Companies, H2 2014 10Number of Products under Investigation by Universities/Institutes, H2 2014 11Comparative Analysis by Clinical Stage Development, H2 2014 12Comparative Analysis by Early Stage Development, H2 2014 13Products under Development by Companies, H2 2014 14Products under Investigation by Universities/Institutes, H2 2014 15Resistant Pseudomonas Aeruginosa Infections - Pipeline by AstraZeneca PLC, H2 2014 16Resistant Pseudomonas Aeruginosa Infections - Pipeline by BiolyticsPharma, H2 2014 17Resistant Pseudomonas Aeruginosa Infections - Pipeline by FOB Synthesis, Inc., H2 2014 18Resistant Pseudomonas Aeruginosa Infections - Pipeline by LegoChem Biosciences, Inc, H2 2014 19 For More Information Visit : www.aarkstore.com

7. List of Figures Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections, H2 2014 8Number of Products under Development for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis, H2 2014 9Number of Products under Development by Companies, H2 2014 10Comparative Analysis by Clinical Stage Development, H2 2014 12Comparative Analysis by Early Stage Products, H2 2014 13Assessment by Monotherapy Products, H2 2014 25Number of Products by Top 10 Targets, H2 2014 27Number of Products by Stage and Top 10 Targets, H2 2014 27Number of Products by Top 10 Mechanism of Actions, H2 2014 29Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 29Number of Products by Top 10 Routes of Administration, H2 2014 31Number of Products by Stage and Top 10 Routes of Administration, H2 2014 31Number of Products by Top 10 Molecule Types, H2 2014 33 For More Information Visit : www.aarkstore.com

8. Browse Full Report Or Sample Request @ http://www.aarkstore.com/healthcare/89708/resistant-pseudomonas-aeruginosa-infections-pipeline-review-h2 For More Information Visit : www.aarkstore.com

9. Related Reports • Healthcare IT (HIT) Market in the APAC Region 2015-2019 • Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report • Colposcopy Test, Market, Users & Forecast - Asia & Middle East Analysis • Asia Intrauterine Device (IUD) Market, Users & Forecast • Global Nuclear Imaging Market 2015-2019 • Point of Care Diagnostic Testing World Markets • European Non-Invasive & Minimally Invasive Cardiac Output Monitoring Devices Market • Europe Laboratory Information System Market For More Information Visit : www.aarkstore.com

10. Follow Us https://www.facebook.com/aarkstoredotcom https://twitter.com/aarkstore https://plus.google.com/+Aarkstoredotcom/posts https://www.linkedin.com/company/aarkstore-enterprise For More Information Visit : www.aarkstore.com

11. Contact Us Office Address Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Mail us at contact@aarkstore.com 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 For More Information Visit : www.aarkstore.com